HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Infliximab therapy for Crohn's-like disease in common variable immunodeficiency complicated by massive intestinal hemorrhage: a case report.

AbstractBACKGROUND:
Common variable immune deficiency is the most frequently encountered immunodeficiency in adults, which is characterized by low levels of serum immunoglobulins. Common variable immune deficiency can present with inflammatory bowel disease-like colitis because of the dysregulated immune system; paradoxically activated T cell receptor pathways are thought to be pivotal in pathogenesis of common variable immune deficiency-related colitis. Treatment for severe complications, such as gastrointestinal bleeding, is not established. We report a case of common variable immune deficiency-related Crohn's-like disease presenting massive melena, which was successfully treated by short course infliximab therapy.
CASE PRESENTATION:
A 26-year-old Japanese man with history of common variable immune deficiency presented with diarrhea, abdominal pain, and fever. Venous administration of antibiotics did not improve his symptoms. Colonoscopy revealed multiple longitudinal ulcers as well as cobblestone-like change in the ileum end and the ascending colon. Histopathological examination of biopsy specimen showed erosion and infiltration of T lymphocytes with lack of B cells. Intravenous hyperalimentation, mesalazine, and steroid did not improve the symptoms and the patient subsequently presented with massive melena. Colonoscopy revealed a protuberant vessel on one of the ulcers in the ascending colon. Endoscopic clipping was repeatedly performed for hemostasis, which was only temporarily successful. In an attempt to manage the bleeding and colitis, a trial of infliximab was given on week 0, week 2 and week 6. Gastrointestinal hemorrhage from the ulcer halted immediately after the first infliximab injection. Colonoscopy performed after the third infliximab showed remarkable improvement in the ileocolitis. No evidence of increased susceptibility to infections was observed and the patient has been in clinical remission for 3 years.
CONCLUSIONS:
We present this case together with review of literature to share our experience of encountering common variable immune deficiency complicating severe Crohn's-like disease and to support that infliximab is a safe and effective treatment that can promptly manage life-threatening intestinal hemorrhage in common variable immune deficiency-related colitis.
AuthorsYuko Akazawa, Fuminao Takeshima, Hiroyuki Yajima, Daisuke Imanishi, Tsutomu Kanda, Kayoko Matsushima, Hitomi Minami, Naoyuki Yamaguchi, Ken Ohnita, Hajime Isomoto, Tomayoshi Hayashi, Masahiro Nakashima, Kazuhiko Nakao
JournalBMC research notes (BMC Res Notes) Vol. 7 Pg. 382 (Jun 22 2014) ISSN: 1756-0500 [Electronic] England
PMID24952714 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal
  • Gastrointestinal Agents
  • Infliximab
Topics
  • Adult
  • Antibodies, Monoclonal (therapeutic use)
  • Common Variable Immunodeficiency (complications)
  • Crohn Disease (drug therapy, etiology)
  • Gastrointestinal Agents (therapeutic use)
  • Gastrointestinal Hemorrhage (etiology, prevention & control)
  • Humans
  • Infliximab
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: